Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Furosemide on Outcome of ESWL
NCT05270421Phase 3Unknown
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of furosemide in nephrolithiasis and ureterolithiasis (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Stone-free rate at 12 weeks. Status: unknown.
02
Drugs
furosemide
03
Conditions
nephrolithiasisureterolithiasis
Beyond the preview
Go deeper on NCT05270421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270421.